Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

The treatment paradigm of non-small-cell lung cancer (NSCLC) has rapidly changed in recent years following the introduction of immune-checkpoint inhibition (ICI). Pre-clinically, both chemotherapy and radiotherapy modulate the tumour microenvironment, providing the rationale for clinical trials eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Priyanka, Alrifai, Doraid, McDonald, Fiona, Forster, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735213/
https://www.ncbi.nlm.nih.gov/pubmed/33293672
http://dx.doi.org/10.1038/s41416-020-01071-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735213/
https://www.ncbi.nlm.nih.gov/pubmed/33293672
http://dx.doi.org/10.1038/s41416-020-01071-5

Ejemplares similares